Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. Welcome to the Orinia Pharmaceuticals third quarter 2025 conference call. Please be advised that a Q&A session will follow Orinia's prepared remarks. I will now turn the call over to Peter Greenlee, President and Chief Executive Officer of Orinia. Thank you all for joining us to discuss Orinia's third quarter 2025 update. Joining me on the call today are Joe Miller, our Chief Financial Officer, and Dr. Greg Keenan, our Chief Medical Officer. Before we begin our discussion, I'd like to direct your attention to slide two, which contains important information regarding forward-looking statements. Additionally, we note that on November 2nd, ARINIA filed a complaint against Dr. George Tidmarsh arising from his statements about Bacillus borum, The complaint is pending in the United States District Court for the District of Maryland and is available online. If you have questions regarding the complaint, we refer you to the complaint itself as we will not be commenting further on this matter. On today's call, we will report third quarter 2025 financial results and provide an update on recent business progress. We're pleased to report that third quarter 2025 loop kind of sales experienced continued momentum following last year's inclusion in the American College of Rheumatology lupus nephritis treatment guidelines, growing at a rate of 27% for the quarter year over year. As a result, we're raising loop kind of sales guidance for 2025 for the second time this year, to 265 million to 270 million. Further, we have conducted new loop kinase data analyses, which we will share shortly, that reinforce loop kinase robust clinical profile in the treatment of patients with lupus nephritis. And lastly, following a positive phase one results that were announced in June, We'...